Loading data for ATYR — first visit, this takes a few seconds.
aTyr Pharma, Inc. (ATYR)
NasdaqCM: ATYR
· 即時價格 · USD
0.50
+0.00 (0.00%)
收盤價： Sep 11, 2026, 3:59 PM
0.43
+0.86%
盤後: 7:59 PM
股價、關鍵數字和最新消息，都在這一頁。
aTyr Pharma, Inc.（ATYR）股價、分析與資料
-0.44% (1D)
| 買價 | 0.35 |
| 市值 | 42.2M |
| 營收 (ttm) | 190K |
| 淨利（ttm） | -60.8M |
| 0.53 | |
| -0.63 | |
| n/a | |
| -0.92 | |
| P/B (ttm) | 0.86 |
| P/S (ttm) | 221.88 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 0.65 |
| 成交量 | 170,000 |
| 20 日平均成交量 | 1,317,685 |
| 開盤價 | 0.51 |
| 前收盤價 | 0.50 |
| 當日區間 | 0.49 - 0.51 |
| 52 週範圍 | 0.40 - 6.50 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis...
完整的公司簡介財報驚奇
aTyr Pharma 已於 Aug 7, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.11 超出預期 0.01, 年增 50.00% 成長.
第 1 頁，共 2 頁